Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PD-0325901 in Advanced Cancer
NCT00147550Phase 2Terminated
- Sponsor
- Pfizer
- Start
- Feb 2004
- Primary completion
- May 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of mirdametinib in breast cancer, colon cancer and melanoma, sponsored by Pfizer. Primary endpoints: Objective Response Rate and Safety. Started Feb 2004; status: terminated.
02
Drugs
mirdametinib
03
Conditions
breast cancercolon cancermelanoma
Beyond the preview
Go deeper on NCT00147550.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00147550.